La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Ascentage Pharma Group a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Ascentage Pharma Group..

Ascentage Pharma Group (NASDAQ:AAPG) Azioni, Catena delle Opzioni

Ascentage Pharma Group

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

market, stock market, Investors,Use,Laptops,To,Analyze,Stock,Market,,Investment,Strategies.,And

Pre-Market Outlook

AAPG

KRUS

MMSI

Penguin Solutions, Inc. - Ordinary Shares

PENG

Un titolo medtech vola del +4,8% dopo una nomina chiave, mentre un altro crolla. La lista dei nomi caldi della giornata.

5 titoli da monitorare oggi che potrebbero sorprendere Wall Street

BTCS Inc. (Nasdaq:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=KSdF_KaaT7aX9ROWw-VMZ9-ZitTy0OqDSsHx_FsmoQDRQoOT-eoqZSjJHZRsYsfyabLElqbPrK3Olaco6W7QSA==">BTCS</a>) ("BTCS" or the "Company") short for Blockchain Technology Consensus Solutions, a blockchain technology-focused company, today announced a funding target increase to $225 million to accelerate the Company's Ethereum accumulation strategy.
The Company's vertically integrated operations, including solo staking through validator nodes and block building, are central to this approach. These activities not only generate recurring, crypto-native revenue but also enhance long-term value per share by compounding ETH-denominated returns.

News

Financing

BTCS

Reported Earlier: BTCS Raises Funding Target To $225M To Accelerate Ethereum Accumulation And Expand Staking Operations

Truist Securities analyst John McDonald maintains PNC Financial Services Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) with a Hold and raises the price target from $189 to $198.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on PNC Financial Services Gr, Raises Price Target to $198

<ul>
<li>Company expands digital asset strategy beyond Bitcoin, including Dogecoin (DOGE), Litecoin (LITE), Solana (SOL), Ripple (XRP), Ether (ETH), USD Coin (USDC)</li>
</ul>
LOS ANGELES, July 9, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4465166-1&amp;h=3576058154&amp;u=https%3A%2F%2Fwww.thumzupmedia.com%2F&amp;a=Thumzup+Media+Corporation">Thumzup Media Corporation</a>&nbsp;("Thumzup" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>), an emerging leader in crypto asset strategies and a social media branding and programmatic marketing solutions, today announced that its Board of Directors has authorized management to begin to accumulate additional cryptocurrencies, specifically Dogecoin (DOGE), Litecoin (LITE), Solana (SOL), Ripple (XRP), Ether (ETH), USD Coin (USDC).
This initiative builds upon Thumzup's previously disclosed Bitcoin ("BTC") acquisition strategy, which permits the Company to hold up to 90% of its liquid assets in BTC. As of July 8, 2025, Thumzup currently holds 19.106 BTC, with a market value of approximately $2.1 million. The Board's latest resolution gives management the authority to evaluate the potential benefits and requirements of diversifying the Company's digital asset portfolio.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

TZUP

Thumzup Expands Crypto Strategy Beyond Bitcoin, Adds DOGE, LTC, SOL, XRP, ETH, And USDC To Portfolio; Holds 19.106 BTC Worth $2.1M

UBS analyst Cleveland Rueckert maintains Ball (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) with a Neutral and raises the price target from $54 to $60.

BALL

UBS Maintains Neutral on Ball, Raises Price Target to $60

Truist Securities analyst John McDonald maintains JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) with a Hold and raises the price target from $280 to $290.

Truist Securities Maintains Hold on JPMorgan Chase, Raises Price Target to $290

UBS analyst Joshua Spector maintains Air Products (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) with a Buy and raises the price target from $328 to $344.

UBS Maintains Buy on Air Products, Raises Price Target to $344

Truist Securities analyst John McDonald maintains Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) with a Buy and raises the price target from $84 to $93.

Truist Securities Maintains Buy on Citigroup, Raises Price Target to $93

Truist Securities analyst John McDonald maintains Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) with a Buy and raises the price target from $51 to $53.

Truist Securities Maintains Buy on Bank of America, Raises Price Target to $53

D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) with a Buy and maintains $16 price target.

FBLG

D. Boral Capital Maintains Buy on FibroBiologics, Maintains $16 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>UBS analyst Dan Leonard downgraded Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) from Buy to Neutral and lowered the price target from $500 to $460. Thermo Fisher Scientific shares closed at $426.17 on Tuesday. <a href="https://www.benzinga.com/quote/tmo/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Ariel Rosa downgraded the rating for Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) from Buy to Neutral and raised the price target from $259 to $288. Norfolk Southern shares closed at $261.20 on Tuesday. <a href="https://www.benzinga.com/quote/nsc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Brandon Nispel downgraded T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) from Sector Weight to Underweight and maintained the price target of $200. T-Mobile shares closed at $235.97 on Tuesday. <a href="https://www.benzinga.com/quote/tmus/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen analyst John Kernan downgraded the rating for PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) from Buy to Hold and lowered the price target from $98 to $74. PVH shares closed at $73.85 on Tuesday. <a href="https://www.benzinga.com/quote/pvh/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst George Staphos downgraded Ball Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) from Buy to Neutral and lowered the price target from $67 to $66. Ball shares closed at $58.76 on Tuesday. <a href="https://www.benzinga.com/quote/ball/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TMO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/TMO/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09102023/image-100-1024x595.png" alt="" class="wp-image-978499" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09102023/image-100-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09102023/image-100-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09102023/image-100-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09102023/image-100.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46296650/top-2-industrials-stocks-you-may-want-to-dump-this-quarter">Top 2 Industrials Stocks You May Want To Dump This Quarter</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Trading Ideas

TMUS

This Thermo Fisher Scientific Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

<a href="https://www.bloomberg.com/news/articles/2025-07-09/samsung-galaxy-watch-8-galaxy-watch-8-classic-prices-features">https://www.bloomberg.com/news/articles/2025-07-09/samsung-galaxy-watch-8-galaxy-watch-8-classic-prices-features</a>

General

GOOG

GOOGL

SSNLF

'Samsung Unveils Redesigned Smartwatches With Google's AI Built In'- Bloomberg

Truist Securities analyst Brian Foran maintains American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) with a Buy and raises the price target from $335 to $340.

Truist Securities Maintains Buy on American Express, Raises Price Target to $340

BWS Financial analyst Hamed Khorsand maintains Adeia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADEA#NASDAQ">ADEA</a>) with a Buy and maintains $18 price target.

ADEA

BWS Financial Maintains Buy on Adeia, Maintains $18 Price Target

Truist Securities analyst Jake Bartlett maintains Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) with a Buy and lowers the price target from $16 to $14.

Truist Securities Maintains Buy on Wendy's, Lowers Price Target to $14

<a href="https://www.benzinga.com/markets/cryptocurrency/25/07/46198393/why-the-future-of-stablecoins-isnt-just-for-humans">Stablecoins are now</a> facilitating nearly $800 billion in digital transactions each month, positioning themselves as credible challengers to traditional payment networks like Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), according to Grayscale's June 2025 market report.
The surge in usage is occurring alongside a wave of favorable regulatory developments and growing corporate interest in stablecoin infrastructure, prompting what some have dubbed "Stablecoin Summer."
What Happened: Grayscale's data reveals that stablecoins, blockchain-based digital dollars typically backed by cash or short-term U.S. Treasuries, have rapidly scaled into one of the most used components of crypto infrastructure.
"Estimates from Visa and crypto data specialists suggest stablecoins are used for about $800 billion in digital transactions per month," the report said. 
For comparison, Visa processed approximately $1.1 trillion in monthly payment volume during 2024.
The report also highlighted Circle&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) public listing in June as a pivotal moment for the sector. 
The issuer of the USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) stablecoin saw its stock rise from $31 to $181 per share by month-end, reflecting strong investor enthusiasm for stablecoin-based business models.
"At that price, Circle trades at more than 150 times its 2024 EBITDA," Grayscale noted.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46318111/xrp-eyes-2-40-as-ripples-rlusd-stablecoin-smashes-500m-market-cap">XRP Eyes $2.40 As Ripple&#8217;s RLUSD Stablecoin Smashes $500M Market Cap</a>
Why It Matters: The regulatory landscape is also shifting.
The U.S. Senate recently passed the GENIUS Act, which establishes a clear legal framework for payment stablecoins, setting rules for reserve assets, compliance procedures, and audit standards. 
The bill now awaits a vote in the House. 
Grayscale believes the legislation will help drive further adoption in the U.S., although it criticizes the Act's ban on interest-bearing stablecoins, calling them a potential benefit to consumers.
Meanwhile, household names outside of the crypto space, including Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), and JPMorgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), are reportedly exploring stablecoin use cases, from internal payment systems to customer-facing integrations. "This is a diverse mix of leading firms, all of which see the potential benefits of stablecoins," Grayscale said.
What&#8217;s Next: While Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) remains the most recognized asset in crypto markets, the report argues that stablecoins and decentralized finance applications are quietly laying the groundwork for broader financial infrastructure shifts.
With stablecoins increasingly used across both emerging markets and institutional channels, the asset class may soon rival or even surpass legacy payment providers in utility and volume.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46309766/most-crypto-apps-assume-youre-online-this-one-works-where-the-internet-doesnt">Most Blockchains Assume You&#8217;re Online — This One Works Where The Internet Doesn&#8217;t</a></li>
</ul>
Image: Shutterstock

$BTC

$USDC

AMZN

CRCL

USDC

Buckle Up, Visa: Stablecoins Process $800 Billion In Transactions Per Month, Report Finds

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09024538/megatronixjpg.jpeg" alt="" class="wp-image-15523" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09024538/megatronixjpg.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09024538/megatronixjpg-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09024538/megatronixjpg-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
After dropping its largest customer, the smart cockpit maker is trying to prove its superior profitability with a "Modularization + Multi-Domain Integration" strategy
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Megatronix has filed for a Hong Kong IPO, reporting its revenue retreated slightly to 1.42 billion yuan last year after a surge in 2023&nbsp;</li>
<li>The smart cockpit maker's losses have narrowed for three consecutive years, but its notes receivable ballooned in 2024</li>
</ul>
Smart cockpits have emerged as a key driver on China's road to more intelligent cars, creating fertile ground for new innovators in the fast-evolving space. Once limited to facilitating interaction between driver and car through voice commands and large touchscreens, such cockpits are now moving to the next level with the inclusion of AI-based natural language processing, visual recognition, contextual interaction, and remote OTA updates. As that happens, a product once considered an add-on and "nice to have" is rapidly becoming a central battlefield for automakers trying to differentiate their products.
The emerging sector has already produced some publicly traded choices for investors, with names like Minieye (2431.HK) listing in Hong Kong. Now, investors could soon have a new choice with the recent application for a Hong Kong listing by&nbsp;Megatronix Inc.
The new wave of software-defined technology powering the smart cockpit 2.0 era has not only reshaped the automotive supply chain but is also spawning a group of "Tier 1.5" suppliers like&nbsp;Minieye&nbsp;and Megatronix. Such companies are positioned between traditional Tier 1 giants like Bosch and Continental and module component suppliers. Other such smart cockpit providers include&nbsp;Autotai&nbsp;and&nbsp;Pateo Connect, which is also&nbsp;<a href="https://thebambooworks.com/pateo-connect-revs-up-for-ipo-belching-widening-losses-and-slumping-margins/">preparing to list</a>&nbsp;in Hong Kong.&nbsp;
New listing candidates like Pateo Connect and Megatronix are hoping to follow in the footsteps of Minieye, whose shares have risen 39% since its trading debut at the end of last year.
Megatronix says its core competitive edge lies in its integrated "Smart Cockpit + X" product philosophy, according to its&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107514/documents/sehk25063001125.pdf">listing document</a>. That means it consolidates various smart vehicle features, including the smart cockpit, advanced driver assistance systems (ADAS) parking, ADAS driving, telematics and OTA updates, into a unified physical domain controller embedded within the vehicle.
Megatronix says its modular, reusable software architecture allows for easy integration into models from different automakers. It says such a "pre-developed module library" approach eliminates the need to reinvent the wheel for every design. That can effectively shorten development and delivery times to months, which is well-suited to China's increasingly "fast cycle, cost-sensitive" auto market.
<h4 class="wp-block-heading">Dropping its largest client</h4>
Megatronix is currently working on products for major automakers such as Chery, Changan, Dongfeng, Changan Mazda, Nissan, and Ford. The company has logged impressive growth since the first model equipped with its products went into mass production in 2022.
Its revenue nearly quadrupled from 388 million yuan ($54 million) in 2022 to 1.51 billion yuan in 2023, before slightly retreating to 1.42 billion yuan last year. Over that time, revenue from its largest customer rose from 205 million yuan in 2022 to 802 million yuan in 2023, before falling back to 324 million yuan last year, dropping from 52.8% of its total in 2022 to a much smaller 22.8% last year.
Last year's drop came after Megatronix decided at the start of 2024 to end its partnership with its largest customer of the previous two years, Desay SV Automotive, a domestic leader in smart cockpits. That decision caused Megatronix's revenue to decline last year, but helped to sharply boost its gross margin from 12.1% in 2023 to 21.8% in 2024.
That shows that Megatronix is putting profits before scale, taking a different approach from many startups that prioritize sales over profitability. Despite losing its largest client, the company significantly boosted its profitability, and also reduced its customer concentration, giving it a healthier base to grow from over the longer term.
Megatronix had partnerships with 12 automakers and secured design wins for 48 vehicle models by the end of last year, with annual shipments exceeding 630,000 units. "Our solutions power one in approximately every 10 new vehicles in China equipped with a smart cockpit domain control system," according to its listing document.&nbsp;
However, like many others in China's automotive supply chain, Megatronix still operates in the red, recording losses of 423 million yuan, 357 million yuan and 291 million yuan from 2022 to 2024, respectively. The company points out its losses are steadily narrowing, which owes to its increasing localization of components, a growing ratio of higher-margin modules in its product mix, and reductions in development costs for new projects using its modular approach.
<h4 class="wp-block-heading">Ballooning notes receivable&nbsp;</h4>
Megatronix held about 187 million yuan in cash at the end of last year, plus another 200 million yuan in restricted cash. But in a worrisome sign, its notes receivable more than quadrupled from 57.19 million yuan in 2023 to 249 million yuan last year. It also had accounts receivable of about 649 million yuan. This shift towards settlement via notes, which are more formal than accounts receivable, is undoubtedly increasing pressure on the company as such notes typically extend the actual cash collection cycle to three to six months or longer.
Megatronix has completed multiple funding rounds since its inception in 2018. The latest came in May this year, when it raised $30.69 million in a round that valued the company at $930 million, close to the rumored $1 billion valuation of Pateo Connect. That said, Megatronix's profitability seems stronger than Pateo Connect's. Megatronix's losses are narrowing, while Pateo Connect's widened by 540 million yuan over the last three years. Megatronix 21.8% gross margin also significantly outperforms Pateo Connect's 11.8% and Minieye's 16%.
The smart cockpit industry is currently transitioning from a cash-burning phase characterized by product development to one of mass production as technologies mature and get incorporated into more models. With its modular platform and pre-development strategy, Megatronix is showing strong system integration capabilities in technical delivery and an ability to control costs. While still unprofitable, its improving gross margins and partnerships with leading automakers appear to position it for further scaled growth and the potential to break even not too far down the road.
The positive investor reception for peers like Minieye is also elevating valuation benchmarks for the smart cockpit sector, creating a favorable listing window for Megatronix. The company could further boost its investor appeal by showing more breakthroughs in diversifying its customer base, improving its cash flow, and expanding its sales overseas.

Asia

Equities

IPOs

Global

Opinion

In 'Warring States Era' for Smart Cockpits, Megatronix Bets On Modular Approach

Truist Securities analyst Jake Bartlett maintains Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) with a Buy and raises the price target from $150 to $160.

SHAK

Truist Securities Maintains Buy on Shake Shack, Raises Price Target to $160

Truist Securities analyst Jake Bartlett maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Buy and raises the price target from $350 to $356.

Truist Securities Maintains Buy on McDonald's, Raises Price Target to $356

Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) has outperformed the market over the past 20 years by 1.56% on an annualized basis producing an average annual return of 10.05%. Currently, Nike has a market capitalization of $110.34 billion. 
Buying $100 In NKE: If an investor had bought $100 of NKE stock 20 years ago, it would be worth $674.35 today based on a price of $74.60 for NKE at the time of writing.
<h3>Nike's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752070532_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Nike 20 Years Ago Would Be Worth This Much Today

Truist Securities analyst Jake Bartlett maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Buy and raises the price target from $63 to $64.

Truist Securities Maintains Buy on Chipotle Mexican Grill, Raises Price Target to $64

Earnings

Press Releases

Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates

Health Care

Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines

Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin

Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax

Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025

Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report

Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors

Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

Management

Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance

Comments

Ascentage Pharma Group

Ascentage Pharma Group (AAPG) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO